Physician profile
Anthony J Meier
NPI 1134236268
$7,303.14
in general payments reported to CMS, 2019-2025
53 companies · $1,274 in 2025
The $1,274 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $483 · 2020: $664 · 2021: $1,181 · 2022: $995 · 2023: $1,311 · 2024: $1,396 · 2025: $1,274.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,981.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,980.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,349.10 | 2021-2025 | |
| Amgen INC. | $798.13 | 2019-2025 | Repatha, Otezla, Otezla |
| Novo Nordisk INC | $763.62 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $339.64 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $333.10 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Otsuka America Pharmaceutical, INC. | $314.84 | 2022-2024 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $313.41 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $295.44 | 2019-2021 | |
| Pfizer INC. | $212.60 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $212.55 | 2020-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $210.19 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $204.85 | 2020-2025 | Airsupra, Breztri, Farxiga |
| Merck Sharp & Dohme LLC | $153.54 | 2019-2024 | Gardasil 9, Vaxneuvance, Gardasil |
| Allergan, INC. | $133.98 | 2019-2020 | |
| Gilead Sciences, INC. | $120.84 | 2019-2022 |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Meier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.